IP Library Granted Patent US 9,017,935
Granted Patent B2
US 9,017,935 · App. 13/551,257 · Granted Apr 28, 2015

HIV-1 latency model for high throughput screening

Inventors: Joseph P. Dougherty (Milford, NJ); Sofiya Micheva-Viteva (Los Alamos, NM); Stuart W. Peltz (Piscataway, NJ); Yacov Ron (Califon, NJ); Annmarie Pacchia (Buffalo, NY)
Assignee: University of Medicine and Dentistry of New Jersey
C12Q1/703C07K14/005C12N15/86C12N2740/16043C12N2740/16122C12Q1/6897
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,017,935
App. No.
13/551,257
Granted
Apr 28, 2015
Kind
B2
Abstract

Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.

Claims (10)

1. An isolated, latently infected T cell line harboring a latent HIV-I derived vector pro virus, which upon activation of the pro virus expresses a secretable marker for late viral gene expression, the gene for said marker being inserted in the position of HIV-I envelope.

2. The cell line of claim 1 , wherein the marker is a secretable enzyme.

3. The cell line of claim 2 , wherein the secretable enzyme is alkaline phosphatase.

4. The cell line of claim 3 , wherein the secreted alkaline phosphatase is capable of being detected using chemiluminescence.

5. The cell line of claim 1 , wherein the pro virus further includes a gene marker for viral early gene expression at the single cell level.

6. The cell line of claim 5 , wherein the expressed marker for viral early gene expression is a fluorescent protein.

7. The cell line of claim 6 , wherein the expressed marker for viral early gene expression is enhanced green fluorescent protein (egfp).

8. The cell line of claim 1 , wherein the provirus is capable of being activated by stimuli selected from the group consisting of tumor necrosis factor (TNF)-α, phorbol 12-myristate 13-acetate (PMA), valporic acid and combinations thereof.

9. The cell line of claim 1 , wherein the provirus contains an intact HIV-I gag gene, thereby allowing the use of Gag expression as a further marker of viral gene expression.

10. The cell line of claim 1 , wherein the latent provirus in the cell line is replication-incompetent.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 27, 2021
From: RUTGERS, THE STATE UNIV OF NJ
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 056991/0895 →
Continuity (3)
Division 12096245
Provisional Application 60742241 · Dec 5, 2005
Related Publication 20130040385A1 · Feb 14, 2013